Albireo Pharma Inc Price/Sales
What is the Price/Sales of Albireo Pharma Inc?
The Price/Sales of Albireo Pharma Inc is 8.58
What is the definition of Price/Sales?
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Price/Sales of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with price/sales similar to Albireo Pharma Inc
- Indian Overseas Bank has Price/Sales of 8.57
- Mirriad Advertising plc has Price/Sales of 8.57
- LXP Industrial Trust has Price/Sales of 8.57
- Alkyl Amines Chemicals has Price/Sales of 8.57
- TradeGo FinTech has Price/Sales of 8.58
- Sprott has Price/Sales of 8.58
- Albireo Pharma Inc has Price/Sales of 8.58
- Beijing PIESAT Information Technology Co has Price/Sales of 8.58
- Mirvac Stapled Securities has Price/Sales of 8.58
- CG Power and Industrial Solutions has Price/Sales of 8.58
- Nuveen Preferred & Income Opportunities Fund has Price/Sales of 8.58
- Zoetis Cl.A Dl ,01 has Price/Sales of 8.58
- Mid-America Apartment Communities has Price/Sales of 8.58